Stockscreener 앱 받기
8.155
3.72%
-0.315
전일 마감가:
$8.47
열려 있는:
$8.44
하루 거래량:
1.83M
Relative Volume:
0.69
시가총액:
$1.79B
수익:
$52.04M
순이익/손실:
$-290.50M
주가수익비율:
-5.6021
EPS:
-1.4557
순현금흐름:
$-240.94M
1주 성능:
-4.12%
1개월 성능:
-16.96%
6개월 성능:
-10.78%
1년 성능:
-29.58%
1일 변동 폭
$8.15
$8.564
1주일 범위
$8.15
$8.86
52주 변동 폭
$6.2301
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
명칭
Ocular Therapeutix Inc
전화
781-357-4000
주소
14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA
Compare OCUL vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
8.155 | 1.89B | 52.04M | -290.50M | -240.94M | -1.4557 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-15 | 개시 | Chardan Capital Markets | Buy |
| 2025-04-08 | 개시 | William Blair | Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-03-11 | 개시 | Needham | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-20 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-02-09 | 개시 | BofA Securities | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-08-10 | 재개 | Berenberg | Buy |
| 2021-08-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-11-13 | 재확인 | Raymond James | Strong Buy |
| 2020-08-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-03 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-05-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-21 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-11-15 | 개시 | Raymond James | Strong Buy |
| 2018-09-07 | 개시 | Piper Jaffray | Overweight |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-26 | 개시 | H.C. Wainwright | Buy |
| 2017-07-12 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-06-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-08-11 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | 개시 | Morgan Stanley | Overweight |
모두보기
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
Ocular Therapeutix Inc (OCUL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OCUL|Ocular Therapeutix Inc|Price:8.505|Chg%:-0.115 - TradingKey
Ocular Therapeutix Inc (OCUL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ocular Therapeutix Inc (OCUL) Cash Flow - TradingKey
Ocular Therapeutix Inc (OCUL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ocular Therapeutix Inc (OCUL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ocular Therapeutix Market Sentiment - Benzinga
Ocular Therapeutix Inc Revenue Breakdown – BX:0OT - TradingView
Ocular Therapeutix Inc (OCUL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Is Ocular Therapeutix (OCUL) Still Undervalued Or Is AXPAXLI Hope Already Priced In? - Yahoo Finance
(OCUL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment - Yahoo Finance
Ocular Therapeutix at H.C. Wainwright: FDA path clears for AXPAXLI By Investing.com - Investing.com South Africa
Ocular Therapeutix at H.C. Wainwright: FDA path clears for AXPAXLI - Investing.com
Ocular Therapeutix, Inc. (OCUL) Stock Analysis: Unpacking The 211% Potential Upside - DirectorsTalk Interviews
Citizens reiterates Ocular Therapeutix stock rating on Dextenza sales - Investing.com
Citizens reiterates Ocular Therapeutix stock rating on Dextenza sales By Investing.com - Investing.com Canada
Ocular Therapeutix Inc (OCUL) Institutional Confidence - TradingKey
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Does Ocular Therapeutix (OCUL) Joining Russell Value Indexes Quietly Recast Its Long‑Term Investor Base? - simplywall.st
FDA approves Dextenza for third indication: Ocular itching from allergic conjunctivitis - Ophthalmology Times Europe
Ocular Therapeutix gives 11 new hires stock awards worth 46,075 shares - Stock Titan
Ocular Therapeutix (OCUL) Joins Russell Value Indexes, Is The Stock Now Too Pricey? - Sahm
Ocular Therapeutix (OCUL) Holds Steady Near Key Support Levels Amid Low VolumeOn Balance Volume - dars.gov.et
Ocular Therapeutix options trading jumps to 9,894 contracts By Investing.com - Investing.com Canada
Ocular Therapeutix options trading jumps to 9,894 contracts - Investing.com
Ocular Therapeutix Inc Actuals & Estimates (NASDAQ:OCUL) - TradingView
Price to earnings forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Ocular Therapeutix Inc to Host Investor Day Transcript - GuruFocus
Enterprise value to revenue forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Price to sales forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Price to book forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Enterprise value to EBIT forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Enterprise value to EBITDA forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Ocular Therapeutix to present new retinal disea... - Pluang
Does Broad Russell Value Index Inclusion Reshape the Bull Case for Ocular Therapeutix (OCUL)? - simplywall.st
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences - The Manila Times
Ocular Therapeutix will present SOL-1 data at July retina meetings - Stock Titan
(OCUL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Ocular Therapeutix, Inc.(NasdaqGM: OCUL) added to Russell 2000 Value Benchmark - marketscreener.com
Ocular Therapeutix (OCUL) Could Be 62% Below Fair Value After Axpaxli FDA Feedback - Sahm
Ocular Therapeutix, Inc.(NasdaqGM: OCUL) added to Russell 2500 Value Benchmark - marketscreener.com
Ocular Therapeutix, Inc.(NasdaqGM: OCUL) added to Russell 3000 Value Benchmark - marketscreener.com
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda? - Stocktwits
OCUL News | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
OCUL Forecast — Price Target — Prediction for 2027 - TradingView
Ocular Therapeutix Inc Actuals & Estimates (BX:0OT) - TradingView
Ocular Therapeutix Inc Actuals & Estimates (HAM:0OT) - TradingView
Chardan Capital Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $23 - Moomoo
OCUL Maintained by Chardan Capital -- Price Target Raised to $23 - GuruFocus
Is Ocular Therapeuticx, Inc. (OCUL) Stock Positioned for Growth After Positive FDA Feedback on Axpaxli? - Yahoo Finance
Ocular Therapeutix Inc (OCUL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.44%
0.02%
자본화:
|
볼륨(24시간):